Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE vs CARDURA XL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.
treatment of symptomatic benign prostatic hyperplasia (BPH),combination therapy for BPH
Benign prostatic hyperplasia (FDA-approved),Hypertension (FDA-approved)
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.
Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours).
15-22 hours in adults; terminal half-life is approximately 22 hours for extended-release formulation, allowing once-daily dosing. Half-life is prolonged in elderly and patients with hepatic impairment.
Dutasteride is extensively metabolized by CYP3A4 and CYP3A5; tamsulosin is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4.
Extensively metabolized in the liver via CYP3A4 and CYP2D6; undergoes O-demethylation and hydroxylation.
Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces.
Primarily hepatic metabolism via CYP3A4, with ~63% of the dose excreted in feces as metabolites and ~9% in urine as unchanged drug. Renal elimination of active drug is minimal (<1%).
Dutasteride: >99.5% bound to albumin and alpha-1-acid glycoprotein. Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein.
~98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Dutasteride: Vd 300-500 L (total body, large tissue distribution). Tamsulosin: Vd 0.2 L/kg (approx 14-30 L, moderate distribution).
1.9-3.1 L/kg, indicating extensive distribution into tissues, including vascular smooth muscle.
Dutasteride: Oral bioavailability ~60% (enhanced with food). Tamsulosin: Oral bioavailability ~30% (increased with food; formulation designed for consistent absorption).
Oral extended-release: ~85% relative to immediate-release formulation, with minimal first-pass metabolism. Food does not significantly affect absorption.
No dosage adjustment is required for renal impairment. Tamsulosin is extensively metabolized and renally excreted as inactive metabolites; however, no specific GFR-based adjustments are recommended.
No dose adjustment required for renal impairment (GFR ≥30 m L/min). For GFR <30 m L/min, use with caution; no specific dose recommendation available.
Dutasteride is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For mild to moderate hepatic impairment (Child-Pugh A or B), no dosage adjustment is recommended, but caution is advised.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), start at 2 mg once daily and titrate cautiously.
Safety and efficacy in pediatric patients have not been established. Use is not recommended in patients under 18 years of age.
Safety and efficacy not established in pediatric patients; no recommended dosing.
No specific dose adjustment is required based on age alone. Elderly patients may be more sensitive to orthostatic hypotension from tamsulosin; monitor blood pressure and advise caution when rising from a seated or lying position.
Initiate at 2 mg once daily with breakfast; titrate slowly to avoid orthostatic hypotension. Monitor blood pressure closely.
None
None.
Orthostatic hypotension/syncope, especially with concurrent antihypertensives,Intraoperative floppy iris syndrome during cataract surgery,Risk of high-grade prostate cancer (increased Gleason score 8-10 with dutasteride),Hepatic impairment may increase exposure,Sexual dysfunction: decreased libido, erectile dysfunction, ejaculation disorders
Orthostatic hypotension and syncope, especially with first dose or dose increase,Priapism (rare),Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery,Hepatic impairment: dose adjustment may be needed
Hypersensitivity to dutasteride, tamsulosin, or other 5α-reductase inhibitors,Women who are or may become pregnant (risk of fetal harm due to androgen inhibition),Severe hepatic impairment (Child-Pugh Class C),History of orthostatic hypotension
Hypersensitivity to doxazosin or any component,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension
Absorption of tamsulosin is decreased when taken with food; however, the combination product should be taken 30 minutes after a meal to maintain consistent exposure. Avoid grapefruit juice as it may increase tamsulosin concentrations. No specific food interactions with dutasteride.
Avoid grapefruit and grapefruit juice as they may increase doxazosin concentrations. No other significant food interactions known. Alcohol may exacerbate hypotensive effects.
Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosin has no known teratogenic risk. First trimester: Dutasteride exposure may cause feminization of male fetuses. Second and third trimesters: Risk persists; avoid use.
Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third trimesters: Potential for reduced placental perfusion due to alpha-blockade; avoid use unless benefit outweighs risk.
Unknown if dutasteride or tamsulosin are excreted in human milk. Dutasteride is lipophilic and may appear in milk. Tamsulosin likely excreted. M/P ratio not available. Due to potential for adverse effects (e.g., hypotension), breastfeeding is not recommended during therapy.
Unknown if excreted in human milk; M/P ratio not available. Caution advised; use only if clearly needed.
No dose adjustment studies in pregnancy. Dutasteride should not be used; tamsulosin is not recommended. No pharmacokinetic changes requiring dose adjustment are established, but avoid use.
No specific dose adjustments established; pharmacokinetics may be altered due to increased plasma volume. Use lowest effective dose and monitor clinical response.
Dutasteride/tamsulosin is a fixed-dose combination for benign prostatic hyperplasia (BPH). Dutasteride is a 5α-reductase inhibitor that reduces prostate volume over months; tamsulosin is an α1-adrenoceptor antagonist providing rapid symptom relief. Do not split or crush capsules. Avoid use in women and children. Monitor for orthostatic hypotension, especially when initiating therapy. Assess for drug-drug interactions: CYP3A4 inhibitors (e.g., ketoconazole) increase dutasteride exposure; tamsulosin interacts with other α-blockers, antihypertensives, and PDE5 inhibitors. Counsel patients about risk of postural hypotension and syncope. Advise patients to avoid driving or hazardous activities until they know how the medication affects them. Dutasteride may cause sexual dysfunction (decreased libido, ejaculatory dysfunction, gynecomastia). Tamsulosin may cause intraoperative floppy iris syndrome during cataract surgery; inform ophthalmologist of use. Monitor serum PSA levels: dutasteride decreases PSA by ~50% after 6 months; establish new baseline. Do not use in patients with history of prostate cancer.
CARDURA XL (doxazosin extended-release) is an alpha-1 adrenergic blocker primarily used for benign prostatic hyperplasia (BPH). Its prolonged action reduces the risk of first-dose syncope compared to immediate-release. Do not crush or chew; swallow whole. Monitor blood pressure in patients also on antihypertensives due to additive hypotensive effects. Avoid use in patients with history of orthostatic hypotension or micturition syncope.
Take this medication once daily, 30 minutes after the same meal each day.,Swallow capsules whole; do not crush, chew, or open.,Rise slowly from sitting or lying down to avoid dizziness or fainting.,Avoid driving or operating machinery until you know how the drug affects you.,Inform your doctor if you plan to have cataract surgery, as this drug may cause complications.,Do not donate blood while taking this medication, as it may harm a fetus if given to a pregnant woman.,Women who are pregnant or may become pregnant should not handle crushed or broken capsules.,Report any breast lumps, pain, or nipple discharge, as gynecomastia is possible.,Use condoms if your partner is pregnant, as dutasteride can be absorbed through skin contact with semen.,Keep all appointments for PSA blood tests; the test result will be lower than expected.,Do not take other alpha-blocker medications for blood pressure or prostate problems while on this drug unless prescribed.,Grapefruit juice may increase side effects; limit or avoid consumption.,Do not stop taking this medication suddenly without consulting your doctor.
Take exactly as prescribed, once daily with or without food. Swallow tablet whole, do not crush or chew.,Avoid grapefruit juice as it may alter drug levels.,Possible side effects include dizziness, fatigue, and nasal congestion. Rise slowly from sitting or lying to reduce fall risk.,May cause orthostatic hypotension especially after first dose or dose increase.,If you experience lightheadedness or fainting, contact your doctor.
"Tamsulosin, an alpha-1 adrenergic antagonist, and fosinopril, an ACE inhibitor, both lower blood pressure through distinct mechanisms, leading to additive hypotensive effects. This synergistic action increases the risk of orthostatic hypotension, dizziness, syncope, and falls, particularly at treatment initiation or dose escalation. The interaction is of clinical concern in elderly patients or those with volume depletion."
"Lofexidine, a central alpha-2 adrenergic agonist, reduces sympathetic outflow and can cause bradycardia and hypotension. Tamsulosin, an alpha-1 adrenergic receptor antagonist, also lowers blood pressure, especially orthostatic. Combined use leads to additive hypotensive effects, increasing risk of symptomatic bradycardia, orthostatic hypotension, syncope, and falls, particularly at therapy initiation or dose titration."
"The combination of tamsulosin and moexipril can lead to an increased risk of hypotension and orthostatic hypotension due to additive vasodilatory effects. Tamsulosin, an alpha-1 adrenergic antagonist, reduces peripheral vascular resistance, while moexipril, an ACE inhibitor, decreases angiotensin II production, further promoting vasodilation. This synergistic effect may cause symptomatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or during dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE vs CARDURA XL, answered by our medical review team.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.. CARDURA XL is a Alpha-1 Blocker Antihypertensive that works by Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE and CARDURA XL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is: One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.. The standard adult dose of CARDURA XL is: 4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE and CARDURA XL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is classified as Category A/B. Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosi. CARDURA XL is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.